Strategic Partnerships Poxel already collaborates with Sumitomo Dainippon Pharma for Imeglimin in multiple markets and expects sales-based payments and royalties, indicating a strong channel for co-development or regional distribution opportunities.

Diversified Portfolio A multi-program pipeline spanning NASH, rare metabolic diseases, and a first-in-class AMPK activator provides multiple entry points for strategic alliances, licensing, or milestone-driven deals to extend reach and revenue streams.

Approved Product TWYMEEG Imeglimin is already approved and launched in Japan, suggesting near-term commercial opportunities, especially in regions where regulatory alignment and partner-led commercialization can be pursued for rapid market entry.

Global Expansion With subsidiaries in Boston and Tokyo and a Paris-listed parent, Poxel is positioned for international collaboration and cross-border partnerships, enabling regional market access and co-marketing arrangements.

Financial Leverage Substantial funding and modest current revenue create a runway for growth-focused business development deals, including upfronts, milestones, and licensing agreements tied to the AMPK and TZD platform programs.